[go: up one dir, main page]

Van Helsdingen et al., 1988 - Google Patents

Behavior and resorption of mitomycin C following multiple intravesical administrations

Van Helsdingen et al., 1988

Document ID
1043403174681424682
Author
Van Helsdingen P
De Bruijn E
Sleeboom H
Rikken C
Tjaden U
Publication year
Publication venue
Journal of pharmaceutical sciences

External Links

Snippet

Although several pharmacological data of intravesical mitomycin C (MMC) are available now, data about resorption following subsequent intravesical instillations with different instillation times are lacking. We have analyzed MMC concentrations in blood plasma and …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Similar Documents

Publication Publication Date Title
Stangou et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis
Beermann et al. Absorption, metabolism, and excretion of hydrochlorothiazide
Rowland et al. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man
Scrobohaci et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers
Briglia et al. The distribution of ethanol in postmortem blood specimens
ICHIKAWA et al. High-performance liquid chromatographic determination of glycyrrhizin and glycyrrhetinic acid in biological materials
Foong et al. Eosinophil‐induced chronic active hepatitis in the idiopathic hypereosinophilic syndrome
Cohen et al. GLC assay for 5-fluorouracil in biological fluids
Pernow et al. Release of endothelin‐like immunoreactivity in relation to neuropeptide Y and catecholamines during endotoxin shock and asphyxia in the pig
Marshall et al. Whole blood serotonin and plasma tryptophan using high-pressure liquid chromatography with electrochemical detection
Schilcher et al. Clinical pharmacokinetics of high-dose mitomycin C
Funakoshi et al. Bioactivity of synthetic human pancreastatin on exocrine pancreas
WO1998009166A1 (en) Method for analysing absorption, distribution, metabolism, excretion (adme) and pharmacokinetics properties of compound mixtures
Van Helsdingen et al. Behavior and resorption of mitomycin C following multiple intravesical administrations
Chen et al. Extensive biliary excretion of the model opioid peptide [D-PEN2, 5] enkephalin in rats
SHIBATA et al. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states
Gyr et al. Flumazenil in the treatment of portal systemic encephalopathy—an overview
Yokagawa et al. Brain regional pharmacokinetics of biperiden in rats
Celio et al. Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva
Mross et al. Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies.
Levêque et al. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer
TAKADA et al. Biological and pharmaceutical factors affecting the absorption and lymphatic delivery of ciclosporin A from gastrointestinal tract
Ueda et al. Concentration-time effects of quinidine disposition kinetics in rhesus monkeys.
Roos et al. Protein binding and erythrocyte partitioning of the antirheumatic proquazone
Plakas et al. Pharmacokinetics, tissue distribution and metabolism of acriflavine and proflavine in the channel catfish (Ictalurus punctatus)